Biology of Blood and Marrow Transplantation
Volume 11, Issue 12 , Pages 945-956 , December 2005

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report

  • Alexandra H. Filipovich

      Affiliations

    • Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio
    • Corresponding Author InformationCorrespondence and reprint requests: Alexandra H. Filipovich, MD, Division of Hematology/Oncology, Cincinnati Children’s Hospital, 333 Burnet Ave., MLC 7015, Cincinnati, OH 45229
  • ,
  • Daniel Weisdorf

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
  • ,
  • Steven Pavletic

      Affiliations

    • National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Gerard Socie

      Affiliations

    • Hopital Saint Louis, Paris, France
  • ,
  • John R. Wingard

      Affiliations

    • University of Florida Shands Cancer Center, Gainsville, Florida
  • ,
  • Stephanie J. Lee

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Paul Martin

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington
  • ,
  • Jason Chien

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington
  • ,
  • Donna Przepiorka

      Affiliations

    • University of Tennessee, Memphis, Tennessee
  • ,
  • Daniel Couriel

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, Texas
  • ,
  • Edward W. Cowen

      Affiliations

    • National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Patricia Dinndorf

      Affiliations

    • US Food and Drug Administration, Rockville, Maryland
  • ,
  • Ann Farrell

      Affiliations

    • US Food and Drug Administration, Rockville, Maryland
  • ,
  • Robert Hartzman

      Affiliations

    • C.W. Bill Young/Department of Defense Marrow Donor Recruitment and Research Program, Naval Medical Research Center, Silver Spring, Maryland
  • ,
  • Jean Henslee-Downey

      Affiliations

    • National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • David Jacobsohn

      Affiliations

    • Children’s Memorial Hospital, Northwestern University School of Medicine, Chicago, Illinois
  • ,
  • George McDonald

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington
  • ,
  • Barbara Mittleman

      Affiliations

    • National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland
  • ,
  • J. Douglas Rizzo

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
  • ,
  • Michael Robinson

      Affiliations

    • National Eye Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Mark Schubert

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington
  • ,
  • Kirk Schultz

      Affiliations

    • University of British Columbia, British Columbia Children’s Hospital, Vancouver, British Columbia, Canada
  • ,
  • Howard Shulman

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington
  • ,
  • Maria Turner

      Affiliations

    • National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Georgia Vogelsang

      Affiliations

    • Johns Hopkins University School of Medicine, Baltimore, Maryland
  • ,
  • Mary E.D. Flowers

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington

Received 9 September 2005 ,Accepted 9 September 2005.

  • Image Result

    Organ scoring of chronic GVHD. *AP may be elevated in growing children, and not reflective of liver dysfunction. †Pulmonary scoring should be performed using both the symptom and pulmonary function te

    Organ scoring of chronic GVHD. *AP may be elevated in growing children, and not reflective of liver dysfunction. †Pulmonary scoring should be performed using both the symptom and pulmonary function testing (PFT) scale whenever possible. When discrepancy exists between pulmonary symptom or PFT scores the higher value should be used for final scoring. Scoring using the Lung Function Score (LFS) is preferred, but if DLCO is not available, grading using FEV1 should be used. The LFS is a global assessment of lung function after the diagnosis of bronchiolitis obliterans has already been established [29]. The percent predicted FEV1 and DLCO (adjusted for hematocrit but not alveolar volume) should be converted to a numeric score as follows: >80% = 1; 70-79% = 2; 60-69% = 3; 50-59% = 4; 40-49% = 5; <40% = 6. The LFS = FEV1 score + DLCO score, with a possible range of 2-12. GVHD indicates graft versus host disease; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; LPS, Lansky Performance Status; BSA, body surface area; ADL, activities of daily living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.

  • Image Result
    Organ scoring of chronic GVHD. *AP may be elevated in growing children, and not reflective of liver dysfunction. †Pulmonary scoring should be performed using both the symptom and pulmonary function te

    Organ scoring of chronic GVHD. *AP may be elevated in growing children, and not reflective of liver dysfunction. †Pulmonary scoring should be performed using both the symptom and pulmonary function testing (PFT) scale whenever possible. When discrepancy exists between pulmonary symptom or PFT scores the higher value should be used for final scoring. Scoring using the Lung Function Score (LFS) is preferred, but if DLCO is not available, grading using FEV1 should be used. The LFS is a global assessment of lung function after the diagnosis of bronchiolitis obliterans has already been established [29]. The percent predicted FEV1 and DLCO (adjusted for hematocrit but not alveolar volume) should be converted to a numeric score as follows: >80% = 1; 70-79% = 2; 60-69% = 3; 50-59% = 4; 40-49% = 5; <40% = 6. The LFS = FEV1 score + DLCO score, with a possible range of 2-12. GVHD indicates graft versus host disease; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; LPS, Lansky Performance Status; BSA, body surface area; ADL, activities of daily living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.

 The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health or the US Government.

PII: S1083-8791(05)00631-2

doi: 10.1016/j.bbmt.2005.09.004

Biology of Blood and Marrow Transplantation
Volume 11, Issue 12 , Pages 945-956 , December 2005